| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky;
2 Department of Pathology and Laboratory Medicine and Department of Medicine, University of Alberta and Canadian Blood Services, Edmonton, Alberta, Canada;
3 Department of Transplantology, Polish-American Children’s Hospital CMUJ, Kracow, Poland;
4 Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, Tennessee
Rhabdomyosarcomas (RMSs) are frequently characterized by bone marrow involvement. Recently, we reported that human RMS cells express the CXC chemokine receptor-4 (CXCR4) and postulated a role for the CXCR4 stromal-derived factor (SDF)-1 axis in the metastasis of RMS cells to bone marrow. Because RMS cells also express the tyrosine kinase receptor c-MET, the specific ligand hepatocyte growth factor (HGF) that is secreted in bone marrow and lymph node stroma, we hypothesized that the c-MET-HGF axis modulates the metastatic behavior of RMS cells as well. Supporting this concept is our observation that conditioned media harvested from expanded ex vivo human bone marrow fibroblasts chemoattracted RMS cells in an HGF- and SDF-1-dependent manner. Six human alveolar and three embryonal RMS cell lines were examined. We found that although HGF, similar to SDF-1, did not affect the proliferation of RMS cells, it induced in several of them: (a) locomotion; (b) stress fiber formation; (c) chemotaxis; (d) adhesion to human umbilical vein endothelial cells; (e) trans-Matrigel invasion and matrix metalloproteinase secretion; and (f) phosphorylation of mitogen-activated protein kinase p42/44 and AKT. Moreover HGF, but not SDF-1, increased the survival of RMS cells exposed to radio- and chemotherapy. We also found that the more aggressive alveolar RMS cells express higher levels of c-MET than embryonal RMS cell lines and "home/seed" better into bone marrow after i.v. injection into immunocompromised mice. Because we could not find any activating mutations in the kinase region of c-MET or any evidence for HGF autocrine stimulation, we suggest that the increased response of RMS cell lines depends on overexpression of functional c-MET. We conclude that HGF regulates the metastatic behavior of c-MET-positive RMS cells, directing them to the bone marrow and lymph nodes. Signaling from the c-MET receptor may also contribute to the resistance of RMS cells to conventional treatment modalities.
This article has been cited by other articles:
|
|
 |
|
  M. Wysoczynski and M. Z Ratajczak Novel Pleiotropic Effects of Thrombin in Regulation of the Metastatic Potential of Human Rhabdomyosarcoma (RMS) Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2270 - 2270. [Abstract]
|
|
|
|
|
|
K. Grymula, M. Tarnowski, R. Maksym, M. Kucia, J. Ratajczak, and M. Z Ratajczak An in Vitro and in Vivo Evidence That Human Rhabdomyosarcomas (RMS) Express Functional CXCR7 Receptor: Overlapping and Distinct Role of CXCR4-SDF-1 and CXCR7-SDF-1/ITAC Axes in Regulating Metastatic Behavior of RMS Cells Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4732 - 4732. [Abstract]
|
|
|
|
|
|
M. Tarnowski, R. Maksym, R. Reca, M. Z Ratajczak, and M. Kucia Expression of CXCR4 and CXCR7 Receptors for Stromal Derived Factor-1 (SDF- 1) Is Differently Regulated in Human Rhabdomyosarcomas (RMS): The Biological Consequences Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4764 - 4764. [Abstract]
|
|
|
|
 |
|
 F. Diomedi-Camassei, H. P. McDowell, M. A. De Ioris, S. Uccini, P. Altavista, G. Raschella, R. Vitali, O. Mannarino, L. De Sio, D. A. Cozzi, et al. Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma Clin. Cancer Res., July 1, 2008; 14(13): 4119 - 4127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-T. Chen, C.-Y. Huang, Y.-Y. Chiang, W.-H. Chen, S.-H. Chiou, C.-Y. Chen, and K.-C. Chow HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wysoczynski, K. Miekus, K. Jankowski, J. Wanzeck, S. Bertolone, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak Leukemia Inhibitory Factor: A Newly Identified Metastatic Factor in Rhabdomyosarcomas Cancer Res., March 1, 2007; 67(5): 2131 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Williamson, J. Selfe, T. Gordon, Y.-J. Lu, K. Pritchard-Jones, K. Murai, P. Jones, P. Workman, and J. Shipley Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma Cancer Res., January 1, 2007; 67(1): 57 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gastaldi, P. Bonvini, F. Sartori, A. Marrone, A. Iolascon, and A. Rosolen Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation Carcinogenesis, September 1, 2006; 27(9): 1758 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Taulli, C. Scuoppo, F. Bersani, P. Accornero, P. E. Forni, S. Miretti, A. Grinza, P. Allegra, M. Schmitt-Ney, T. Crepaldi, et al. Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma. Cancer Res., May 1, 2006; 66(9): 4742 - 4749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Patane, S. Avnet, N. Coltella, B. Costa, S. Sponza, M. Olivero, E. Vigna, L. Naldini, N. Baldini, R. Ferracini, et al. MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Res., May 1, 2006; 66(9): 4750 - 4757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-R. Son, L. A. Marquez-Curtis, M. Kucia, M. Wysoczynski, A. R. Turner, J. Ratajczak, M. Z. Ratajczak, and A. Janowska-Wieczorek Migration of Bone Marrow and Cord Blood Mesenchymal Stem Cells In Vitro Is Regulated by Stromal-Derived Factor-1-CXCR4 and Hepatocyte Growth Factor-c-met Axes and Involves Matrix Metalloproteinases Stem Cells, May 1, 2006; 24(5): 1254 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Bartolome, I. Molina-Ortiz, R. Samaniego, P. Sanchez-Mateos, X. R. Bustelo, and J. Teixido Activation of Vav/Rho GTPase Signaling by CXCL12 Controls Membrane-Type Matrix Metalloproteinase-Dependent Melanoma Cell Invasion Cancer Res., January 1, 2006; 66(1): 248 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vasyutina, J. Stebler, B. Brand-Saberi, S. Schulz, E. Raz, and C. Birchmeier CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells Genes & Dev., September 15, 2005; 19(18): 2187 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kucia, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis Stem Cells, August 1, 2005; 23(7): 879 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hu, X. Deng, X. Bian, G. Li, Y. Tong, Y. Li, Q. Wang, R. Xin, X. He, G. Zhou, et al. The Expression of Functional Chemokine Receptor CXCR4 Is Associated with the Metastatic Potential of Human Nasopharyngeal Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4658 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wysoczynski, R. Reca, J. Ratajczak, M. Kucia, N. Shirvaikar, M. Honczarenko, M. Mills, J. Wanzeck, A. Janowska-Wieczorek, and M. Z. Ratajczak Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient Blood, January 1, 2005; 105(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-R. Son, D. Zhao, L. A. Marquez-Curtis, N. Shirvaikar, M. Z. Ratajczak, and A. Janowska-Wieczorek SDF-1-CXCR4 and HGF-c-met Axes Regulate Mobilization/Recruitment to Injured Tissue of Human Mesenchymal Stem Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2331 - 2331. [Abstract]
|
|
|
|
 |
|
 I. Tegeder and G. Geisslinger Opioids As Modulators of Cell Death and Survival--Unraveling Mechanisms and Revealing New Indications Pharmacol. Rev., September 1, 2004; 56(3): 351 - 369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
